Skip to content

Free cash flow at other companies

ALN
Alnylam PharmaceuticalsALNY
$48.67M+138%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$26.47M-11.5%
Regenxbio logo
RegenxbioRGNX
-$77.42M-337%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$3M+1,296%
Opko Health logo
Opko HealthOPK
-$21.14M+44.0%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$48.62M+17.8%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Calculated from Tectonic Therapeutics’s reported figures.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's free cash flow?
Tectonic Therapeutics (TECX) reported free cash flow of -$18.43M in Q1 2026.
How has Tectonic Therapeutics's free cash flow changed year-over-year?
Tectonic Therapeutics's free cash flow decreased by 40.6% year-over-year, from -$13.11M to -$18.43M.
What is the long-term trend for Tectonic Therapeutics's free cash flow?
Over 4 years (2021 to 2025), Tectonic Therapeutics's free cash flow has grown at a -12.0% compound annual growth rate (CAGR), from -$100.49M to -$60.29M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.